Scholars@Duke
Chenyu Lin

Chenyu Lin

Assistant Professor of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy

Selected Publications

Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Related CRS and ICANS - A Multicenter Retrospective Analysis.

Journal Article Blood Adv · October 22, 2024 Chimeric Antigen Receptor T-Cell therapies (CAR-T) are effective in many hematologic malignancies; however, adverse events including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) can affect a significant ... Full text Link to item Cite

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.

Journal Article J Clin Oncol · October 17, 2024 PURPOSE: On the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October 2021 for adults with relapsed/refractory ( ... Full text Link to item Cite

Comprehensive Genomic Profiling in Non-Myeloid Hematologic Malignancies Identifies Variants That Can Alter Clinical Practice

Journal Article Hematology Reports · September 30, 2024 Background: Comprehensive genomic profiling (CGP) is frequently adopted to direct the clinical care of myeloid neoplasms and solid tumors, but its utility in the care of lymphoid and histiocytic cancers is less well defined. Methods: In this study, ... Full text Cite

A Multicenter Phase II Clinical Trial of Low-Dose Subcutaneous Decitabine in Myelofibrosis.

Journal Article Blood advances · September 2024 Myelofibrosis (MF) in the chronic phase is a challenging disease entity to treat, and conventional treatment options are geared towards symptom palliation. In this prospective, multicenter, phase II trial, 21 patients with myelofibrosis (18 chronic-phase, ... Full text Cite

Impact of Prior Inotuzumab Ozogamicin Treatment on Brexucabtagene Autoleucel outcomes in Adults with B-cell ALL.

Journal Article Blood Adv · August 2, 2024 The effect of prior inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu-cel) outcomes remains unclear in adults with acute lymphoblastic leukemia (ALL), particularly the influence off previous InO response and the timing of administra ... Full text Link to item Cite

Dasatinib-associated follicular lymphoma in a patient with B-cell acute lymphoblastic leukaemia.

Journal Article BMJ Case Rep · May 17, 2023 The tyrosine kinase inhibitor dasatinib is approved for the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL). Patients on dasatinib can rarely develop a form of benign reversible reactive ... Full text Link to item Cite

A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.

Journal Article Transplant Cell Ther · March 2023 Featured Publication Despite the exciting advancement of novel therapies, chronic graft-versus-host disease (cGVHD) remains the most common cause of non-relapse mortality after allogeneic hematopoietic stem cell transplantation (HCT). Frontline treatment of cGVHD involves syst ... Full text Link to item Cite

Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma.

Journal Article Cancer Invest · January 31, 2023 MT-3724 is an engineered direct-kill immunotoxin comprised of a CD20-specific scFv fused to a Shiga-like toxin subunit. In this phase IIa study, eight patients with relapsed diffuse large B-cell lymphoma were treated with MT-3724 combined with gemcitabine ... Full text Link to item Cite

Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.

Journal Article Int J Mol Sci · December 22, 2022 Numerous recent advancements in T-cell based immunotherapies have revolutionized the treatment of hematologic malignancies. In the race towards the first approved allogeneic cellular therapy product, there is growing interest in utilizing natural killer (N ... Full text Link to item Cite

Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Journal Article Cancer Invest · November 2021 Novel therapeutics are needed for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Everolimus is an mTOR pathway inhibitor with synergistic anti-tumor activity when combined with histone deacetylase inhibitors, such as panobi ... Full text Link to item Cite

Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer.

Journal Article Breast Cancer Res Treat · June 2021 BACKGROUND: Clinical and genomic data from patients with early-stage breast cancer suggest more aggressive disease in premenopausal women. However, the association between age, disease course, and molecular profile from liquid biopsy in metastatic breast c ... Full text Link to item Cite

Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools.

Journal Article Eur J Cancer · January 2021 BACKGROUND: Liquid biopsy provides real-time data about prognosis and actionable mutations in metastatic breast cancer (MBC). The aim of this study was to explore the combination of circulating tumour DNA (ctDNA) analysis and circulating tumour cells (CTCs ... Full text Link to item Cite

Long-term antithrombotic therapy after venous stent placement.

Journal Article Phlebology · July 2020 OBJECTIVES: To examine the prescribing patterns and outcomes of antithrombotic regimens after venous stent placement. METHODS: A total of 87 patients who received inferior vena cava or iliofemoral venous stents were included in the study. A retrospective r ... Full text Link to item Cite

Emerging Role of Genomics and Cell-Free DNA in Breast Cancer.

Journal Article Curr Treat Options Oncol · June 29, 2019 Precision Medicine is gaining momentum as the future gold standard healthcare strategy as it enables treatment optimization and consequently a potential improvement for quality of life and survival. This paradigm shift was possible thanks to new high-throu ... Full text Link to item Cite

Engineering alternate cooperative-communications in the lactose repressor protein scaffold

Journal Article Protein Engineering Design and Selection · June 1, 2013 Full text Cite